Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%–5% of all NSCLC patients. ALK+ NSCLC cells re...

Descripción completa

Detalles Bibliográficos
Autores principales: Chia, Puey Ling, Mitchell, Paul, Dobrovic, Alexander, John, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242069/
https://www.ncbi.nlm.nih.gov/pubmed/25429239
http://dx.doi.org/10.2147/CLEP.S69718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242069/
https://www.ncbi.nlm.nih.gov/pubmed/25429239
http://dx.doi.org/10.2147/CLEP.S69718

Ejemplares similares